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PPARs play a pivotal role in regulating lipid and glucose homeostasis and are involved in diverse biological activities in skin.
Pomegranate ﬂower (PGF, an antidiabetic therapy in Unani and Ayurvedic medicines) has been previously demonstrated to
activate both PPARalpha/gamma. Here, we found that treatment of mice with the diet containing PGF powder over 55 weeks
attenuated ageing-induced abnormal increases in the homeostasis model assessment of insulin resistance, glucose concentrations
during oral glucose tolerance test, and adipose insulin resistance index. The diet tended to decrease the excessive peri-ovary
fat mass. It, however, increased the thinned subcutaneous fat thickness. In addition, the diet restored decreases in skin water
content, epidermis thickness, and collagen density in corium. Thus, our results demonstrate that long-term treatment with the
Unani and Ayurvedic therapy ameliorates ageing-induced insulin resistance, which is associated with reversal of ageing-induced
fat redistribution. Further, PGF attenuates ageing-mediated undesirable skin abnormalities.
1.Introduction
Ageing is an important risk factor for most of the com-
mon diseases, such as type 2 diabetes and cardiovascular
diseases. A fundamental process associated with ageing is
dysregulation of energy homeostasis [1]. Advance in age is
frequently associated with impaired glucose handling and a
decline in glucose tolerance [1, 2]. Insulin plays a pivotal role
in regulating glucose metabolism. Insulin resistance is the
fundamental defect in type 2 diabetes and closely associated
with obesity, dyslipidemia, and cardiovascular diseases [3].
On the other hand, the skin, one of the largest organs of the
body,isaﬀectedfrequentlyby theageingprocess. Skin ageing
leads to a direct reduction in water and collagen contents,
thereby weakening skin functions [4].
Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated transcription factors belonging to the
steroid nuclear receptor family. Three diﬀerent isoforms
(α, β/δ,a n dγ) have been identiﬁed and play a key role
in the transcriptional regulation of genes responsible for
the control of lipid and glucose metabolism [5]. PPARγ
and PPARα are molecular targets for the insulin-sensitizers
thiazolidinediones and the lipid-lowering drugs ﬁbrates,
respectively[6].PPARsarealsoinvolvedinvariousbiological
activities in epidermis, such as keratinocyte proliferation and
diﬀerentiation, epidermal barrier maturation and recovery,
sebocyte activity, and melanocyte diﬀerentiation [7]. Due
to their diverse functions in skin biology, PPARs are also
researchtargetsfortheunderstandingandtreatmentofmany
skin diseases.2 Evidence-Based Complementary and Alternative Medicine
Punica granatum Linn, commonly known as pomegra-
nate, belongs to the Punicaceae family. Pomegranate ﬂower
(PGF) is an antidiabetic remedy in Unani and Ayurvedic
medicines [8, 9]. In China, the ﬂower has been also used in
thetreatmentofgreyhairinyoungmen[10], suggesting that
PGF may have antiageing property. PGF prominently con-
tainspolyphenols(321±8mg/gintheethanolicextract,such
as gallic acid and ellagic acid) and triterpenoids (oleanolic
acid and ursolic acid) [11]. It has been demonstrated that
PGF extract decreases blood glucose concentration in young
diabetic animals [11–14].
We have recently identiﬁed PGF as a dual PPARα/γ
activator [11–13]. PGF extract and oleanolic acid were
found to speciﬁcally enhance PPARα luciferase reporter gene
activity in human embryonic kidney 293 cells [13], while the
extract and polyphenols gallic acid and ellagic acid activate
PPARγ-mediated gene expression and activity [12, 15, 16].
In addition, both oleanolic acid and ursolic acid have been
shown to induce PPARα expression in human skin cell line
HaCaT [17, 18].
It has been suggested that some of the existing therapies
for metabolic diseases might exert beneﬁcial eﬀects by
tapping into the machinery that regulates ageing [1]. In
contrast, the drugs targeting the mechanisms of ageing are
inherently more valuable than drugs ameliorating only the
disease by treating the symptoms [1]. We speculated that
PGF, the herb with dual PPARα/γ activator properties might
meet this criterion. In this context, we in the present study
investigated the eﬀects of long-term treatment with PGF on
ageing-associated metabolic abnormalities and skin changes
in mice.
2.MaterialsandMethods
2.1. Pomegranate Flower (PGF). PGF was collected in Maha-
rashtra state, India. PGF was identiﬁed and characterized by
HPLC to contain 0.82% gallic acid, 0.79% oleanolic acid,
and 0.26% ursolic acid in methanolic extract [11–13]. Dried
PGFs were grounded into a ﬁne powder and mixed with a
standard diet containing water 8.2%, crude protein 20.4%,
crude fat 6.9%, ash 5.6%, ﬁber 1.7%, and soluble nonnitrate
57.2% (Oriental Yeast, Chiba, Japan) at the ratio of 0.25%
PGF or 0.5% PGF (w/w).
2.2. Animals and Experimental Protocol. All experimental
procedures were carried out in accordance with the Guiding
Principles for the Care and Use of Laboratory Animals
approved by The Japanese Pharmacological Society [http://
plaza.umin.ac.jp/JPS1927/jps/Animal.pdf].FemaleddYmice
aged 4 weeks (Kiwa Laboratory Animals, Wakayama, Japan)
were housed (3 mice per cage) in an air-conditioned
room at 23 ± 1◦C and 50–70% relative humidity with a
12-hour light/dark cycle. Mice were provided ad libitum
with water and a standard diet. Animals were allowed
free access to the food and water for 1 week before the
experiments commenced. After one-week acclimation, 18
mice were divided into 3 groups (6 mice each group): old
control, old 0.25% PGF, and old 0.5% PGF. Body weights
were comparable between the groups before treatments
commenced (Figure 1(c)). Mice in old 0.25% PGF group
were fed the diet containing 0.25% PGF powder, while mice
in old 0.5% PGF group were given the diet containing 0.5%
PGF powder for 55 weeks. Animals in old control groupwere
given the corresponding standard diet only. Food intake and
bodyweightweredeterminedatweek53.Additional6female
ddY mice aged 5 weeks (after one-week acclimation) were
used as young controls. Oral glucose tolerance tests (OGTT)
were performed at week 54. Animals were weighed again at
week 55 and then killed by prompt dislocation of the neck
vertebra. Peri-ovary white adipose tissue was collected and
weighed. Dorsal skin with subcutaneous fat tissue was also
collected for water content determination and histological
examination.
2.3. Oral Glucose Tolerance Test (OGTT). Mice were fasted
overnight with free access to water before OGTT. Mice
received a glucose solution (2g/kg) by gavage. Blood samples
were collected prior to and 20, 60, and 120min after admin-
istration of glucose solution for determination of plasma
concentrations of glucose and/or insulin, total cholesterol,
triglyceride and non-esteriﬁed fatty acids (NEFA). The
homeostasismodelassessmentofinsulinresistance(HOMA-
IR) index was calculated according to the following formula:
[insulin (μIU/mL) × glucose (mM)]/22.5 [19, 20]. Glucose
concentration area under curve (AUC) was calculated.
Adipose insulin resistance (Adipo-IR) index was calculated
as the following formula described previously [19]: [Adipo-
IR = fasted insulin (mmol/L) × fasted NEFA (pmol/L)].
2.4. Blood Biochemical Determination. Plasma concentra-
tions of glucose, total cholesterol, triglyceride, and NEFA
were determined using commercial enzymatic methods (kits
from Wako, Osaka, Japan). Plasma insulin concentrations
were determined by ELISA (kit from Morinaga, Tokyo,
Japan).
2.5. Determination of Skin Water Content. A portion of wet
dorsal skin tissue (≈1g) was weighed, minced, and dried in a
tubeat80◦Cuntilaconstantweightwasobtained.Skinwater
content was calculated as g/g wet tissue.
2.6. Histological Examination. A portion of skin together
with subcutaneous fat tissue was ﬁxed with 10% formalin
a n de m b e d d e di np a r a ﬃn. 4-micron sections were cut
and stained with Mason’s staining for examination of skin
histology (IX-81, Olympus Corporation, Tokyo, Japan). The
epidermis thickness, corium collagen density (histogram),
and subcutaneous fat thickness were measured using an
ImageJ 1.43 analyzing system. At least 100 measurements
from 5 individual ﬁelds were performed for each animal.
2.7. Data Analysis. All results are expressed as means ±
SEM. Data were analyzed by 1-factor analysis of variance
(ANOVA). If a statistically signiﬁcant eﬀect was found, the
Newman-Keuls test was performed to isolate the diﬀerenceEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: The eﬀects of PGF powder on the fasted plasma glucose (a) and insulin (b) concentrations, the index of the homeostasis model
assessment of insulin resistance (HOMA-IR) (c), and glucose concentrations (d) and AUC (e) during oral glucose tolerance testing (glucose
dosage: 2g/kg) in old female ddY mice. Animals consumed the diet containing 0.25%, 0.5% pomegranate ﬂower (PGF), or a standard diet
for 55 weeks. The corresponding young mice were used as young controls. Data are means ± SEM (n = 6 each group) versus old control,
∗P < 0.05.
between the groups. P values less than 0.05 were considered
as indicative of signiﬁcance.
3. Results
3.1. Eﬀects of PGF on Ageing-Associated Metabolic Variables in
Mice. The fasted old animals appeared to increase in plasma
glucose (Figure 1(a)) insulin concentrations (Figure 1(b)),
and HOMA-IR index (Figure 1(c)). In the OGTT assess-
ments, plasma glucose concentrations at 20 and 120min
after exogenous glucose stimulation (Figure 1(d)), as well
as glucose AUC (Figure 1(e)), were also signiﬁcantly higher
(Figure 1(d)). Consumption of 0.5% PGF diet showed a
trend to decrease the concentrations of fasted glucose and
insulin. The most signiﬁcant eﬀects appeared to be on
the decrease of HOMA-IR index and the inhibition of the
abnormal increase in plasma glucose concentrations at 20
and 120min, and glucose AUC in OGTT. Consumption of
0.25% PGF diet showed lesser eﬀect on the plasma glucose
and insulin concentrations, as well as HOMA-IR index.
Compared to the corresponding young controls, the old
mice exhibited increased fasted plasma triglyceride concen-
trations (Figure 2(b)), whereas fasted plasma total choles-
terol (Figure 2(a)) and NEFA concentrations (Figure 2(c))
were not signiﬁcantly diﬀerent between young and old con-
trols. However, Adipo-IR index was signiﬁcantly increased
in old mice (Figure 2(d)). Consumption of 0.5% PGF
diet decreased Adipo-IR index but did not signiﬁcantly
decrease plasma total cholesterol, triglyceride, and NEFA
concentrations. 0.25% PGF diet did not signiﬁcantly aﬀect
all these variables.4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: The eﬀects of PGF powder on the fasted plasma concentrations of total cholesterol (a), triglyceride (b), nonesteriﬁed fatty acids
(NEFA)(c),andadiposeinsulinresistance(Adipo-IR)index(d)inoldfemaleddYmice.Animalsconsumedthedietcontaining0.25%,0.5%
pomegranate ﬂower (PGF) or a standard diet for 55 weeks. The corresponding young mice were used as young controls. Data are means ±
SEM (n = 6 each group) versus old control,
∗P < 0.05.
There was no diﬀerence in food intake between young
and old controls (Figure 3(a)). However, the ratio of food
intake to body weight was markedly decreased in old mice
compared to young controls (Figure 3(b)). Body weight
(Figure 3(c)), peri-ovary fat weight (Figure 3(e)), and the
ratio of peri-ovary fat weight to body weight (Figure 3(f))a t
the endpoint of the experiment were markedly increased in
old controls compared to the corresponding young controls.
In contrast, subcutaneous fat thickness (Figures 4(a) and
4(b)) were decreased by one-third in old mice compared to
young controls. Treatment with 0.5% PGF diet signiﬁcantly
increased food intake (Figure 3(a)) and partially restored the
decreased ratio of food intake to body weight (Figure 3(b)).
This treatment also showed a trend to decrease peri-ovary fat
weight (Figure 3(e)) and the ratio of peri-overy fat weight
to body weight (Figure 3(f)), but did not aﬀect body
weight (Figure 3(c)) and body weight gain (Figure 3(d)).
Furthermore, it signiﬁcantly restored the decline of subcuta-
neous fat thickness (Figures 4(a) and 4(b)). 0.25% PGF diet
showedminimaleﬀectonallvariables(Figures3(a)–3(f)and
4(a)and 4(b)).
3.2. Eﬀects of PGF on Ageing-Associated Skin Changes in Mice.
The skin water content (Figure 5(a)), epidermis thickness
(Figures 5(b) and 5(d)), and histogram of Mason’s stained
area in corium (reﬂecting the density of collagen accumula-
tion) (Figures 5(c) and 5(d)) in old mice were decreased by
one-third, compared to those of young controls. Consump-
tion of 0.5% PDF diet signiﬁcantly restored the declines ofEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: The eﬀects of PGF powder on the average food intake (a), ratio of food intake to body weight (b), body weights (c), body weight
gain (d), peri-ovary fat weight (e), and ratio of peri-ovary fat weight to body weight (f) in old female ddY mice. Animals consumed the diet
containing 0.25%, 0.5% pomegranate ﬂower (PGF), or a standard diet for 55 weeks. The corresponding young mice were used as young
controls. Data are means ± SEM (n = 6 each group). BW, body weight; versus old control,
∗P < 0.05.
these variables, while 0.25% PDF diet showed minimal eﬀect
(Figures 5(a)–5(d)).
4. Discussion
In the present study, old mice showed an increase in
HOMA-IR index and a decline in glucose clearance in the
OGTT assessments, suggesting ageing-associated insulin
resistance. Consumption of 0.5% PGF diet reduced the
increased HOMA-IR index and inhibited the abnormal
increase in glucose concentrations and AUC during OGTT
in old mice. Thus, these results suggest that PGF ameliorates
ageing-associated insulin resistance. Obesity is a well-estab-
lished metabolic risk factor. Increased adipose tissue mass,
especially in the visceral compartment, represents one of the
major risk factors for the development of type 2 diabetes
[21]. An increase in visceral fat mass appears to be a risk
factor for type 2 diabetes; by contrast, when majority of
the fat is deposited subcutaneously and visceral fat mass is
low, obese individuals are relatively healthy [22, 23]. Old
individuals experience a progressive redistribution of fat
fromsubcutaneoustovisceralregions,makingsubcutaneous
fat tissue thinner and abdominal fat tissue greater [24–26].
The increase in visceral fat and decrease in subcutaneous fat
contributes to the insulin resistance that occurs in peripheral
tissues [1, 27–29]. It has been demonstrated that reduction
of plasma insulin concentrations by the PPARα agonist
fenoﬁbrate is accompanied by a decrease in visceral fat
mass in high-fat-diet-fed rats [7, 30] or in lipogenic, simple-
carbohydrate-diet-fedmice[31].Incontrast,ameliorationof
insulin sensitivity by the PPARγ agonists, pioglitazone, and
rosiglitazone,isaccompaniedbyanincreaseinsubcutaneous
fat mass, but not in visceral fat weight in obese rats [30, 32],
and also in the patients with type 2 diabetes [33]. In the6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: The eﬀects of PGF powder on the subcutaneous fat thickness (a) and representative images showing histology of subcutaneous fat
tissue (Mason’s staining, ×100) (b) in old female ddY mice. Animals consumed the diet containing 0.25%, 0.5% pomegranate ﬂower (PGF),
or a standard diet for 55 weeks. The corresponding young mice were used as young controls. Data are means ± SEM (n = 6 each group)
versus old control,
∗P < 0.05.
present study, old mice showed an increase in peri-ovary
(visceral) fat mass and a decrease in subcutaneous fat
thickness. This redistribution of fat was reversed after long-
term consumption of PGF diet. Furthermore, the increased
Adipo-IR index (indicating insulin sensitivity in adipose
tissue,[19])wasalsoattenuated.Thus,itislikelythatreversal
of fat redistribution is involved in PGF consumption-elicited
amelioration of ageing-associated insulin resistance. These
positive consequencesmay be as a result of the dual PPARα/γ
activator properties of PGF.
The consumed food was similar in old mice to their
correspondingyoungcontrols.Additionally,theratiooffood
intake to body weight was much lower in old mice than their
corresponding young controls. However, the body weights
and peri-ovary fat mass were much higher in old mice. These
results suggest an ageing-associated decrease in nutrition
metabolism (energy expenditure). Interestingly, PGF treat-
ment increased food intake and the ratio of food intake to
body weight in old mice. Nevertheless, this treatment did not
increase body weight. It has been demonstrated previously
that the PPARγ agonists rosiglitazone [32] and pioglitazone
[30] increase food intake. Thus, the PPARγ activator [13]
property of PGF possibly contributes to the increased food
intake.
PPARγ is not expressed in mouse and human ker-
atinocytes [34, 35]. In contrast, upregulation of PPARα can
be observed in the interfollicular epidermis upon prolifera-
tion by stimuli or hair plucking and during wound healing
[34]. During epidermal diﬀerentiation, the expression of
PPARα increases, and stimulation of PPARα increases the
synthesis of cholesterol and ceramides in keratinocytes [36].
PPARα activators profoundly inﬂuence lipid metabolism
in reconstructed epidermis [37]. It has been demonstrated
that oleanolic acid and ursolic acid, both of which are
contained in PGF [11], induce the diﬀerentiation of human
keratinocytes via a PPARα pathway [17, 18]. Furthermore,
treatment of hairless mice with these compounds increases
epidermis thickness, enhancesthe recoveryof epidermal per-
meability barrier function after disruption by tape stripping,
and increases ceramide content and hydration levels in skin
[17, 18]. The prescription of PGF for grey hair in Traditional
ChineseMedicine[10]hassuggestedthepotentialoftheherb
in skin ageing. In the present study, ageing induced substan-
tial decrease in skin water content, epidermis thickness, and
collagen density in corium. PGF treatment attenuated these
declines.TheseresultsdemonstratethebeneﬁtofPGFtoskin
ageing. PPARα activation by PGF likely plays a role in these
eﬀects.Evidence-Based Complementary and Alternative Medicine 7
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Figure 5: The eﬀects of PGF powder on the skin water content (a), epidermis thickness (b), collagen histogram in corium (c), and
representative images showing histology of epidermis and corium collagen density (Mason’s staining, ×100) (d) in old female ddY mice.
Animals consumed the diet containing 0.25%, 0.5% pomegranate ﬂower (PGF), or a standard diet for 55 weeks. The corresponding young
mice were used as young controls. Data are means ± SEM (n = 6 each group) versus old control,
∗P < 0.05.
5. Conclusion
The present study demonstrates that the Unani and
Ayurvedic medicine pomegranate ﬂower ameliorates ageing-
associatedinsulinresistance,whichisassociatedwithreversal
of ageing-induced fat redistribution from subcutaneous to
visceral regions. In addition, PGF attenuates ageing-mediat-
ed undesirable skin changes. This study provides potentially
important results that may lead to further research, which
supports and extends these ﬁndings to clinical trials.
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